DK0565620T3 - Mitotoxin til behandling af karbeskadigelse - Google Patents

Mitotoxin til behandling af karbeskadigelse

Info

Publication number
DK0565620T3
DK0565620T3 DK92903777.8T DK92903777T DK0565620T3 DK 0565620 T3 DK0565620 T3 DK 0565620T3 DK 92903777 T DK92903777 T DK 92903777T DK 0565620 T3 DK0565620 T3 DK 0565620T3
Authority
DK
Denmark
Prior art keywords
ligand
treated
cytotoxic agent
conjugate
vascular injury
Prior art date
Application number
DK92903777.8T
Other languages
Danish (da)
English (en)
Inventor
Douglas A Lappi
Ward Casscells
Andrew J Baird
Original Assignee
Salk Inst For Biological Studi
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salk Inst For Biological Studi, Us Health filed Critical Salk Inst For Biological Studi
Application granted granted Critical
Publication of DK0565620T3 publication Critical patent/DK0565620T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pretreatment Of Seeds And Plants (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
DK92903777.8T 1991-01-03 1992-01-02 Mitotoxin til behandling af karbeskadigelse DK0565620T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63707491A 1991-01-03 1991-01-03

Publications (1)

Publication Number Publication Date
DK0565620T3 true DK0565620T3 (da) 1996-01-22

Family

ID=24554442

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92903777.8T DK0565620T3 (da) 1991-01-03 1992-01-02 Mitotoxin til behandling af karbeskadigelse

Country Status (7)

Country Link
US (1) US5308622A (fr)
EP (1) EP0565620B1 (fr)
AT (1) ATE128034T1 (fr)
AU (1) AU1193492A (fr)
DE (1) DE69204990T2 (fr)
DK (1) DK0565620T3 (fr)
WO (1) WO1992011872A1 (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5529932A (en) * 1988-01-28 1996-06-25 Pharmacia, S.P.A. Isolated DNA encoding a plant ribosome inactivating protein from the leaves of saponaria officinalis
US5635384A (en) * 1990-06-11 1997-06-03 Dowelanco Ribosome-inactivating proteins, inactive precursor forms thereof, a process for making and a method of using
US5478804A (en) * 1990-09-19 1995-12-26 The Salk Institute For Biological Studies Treatment of tumorigenic pathophysiological conditions with FGF-cytoxic conjugates
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
GB9203533D0 (en) * 1992-02-19 1992-04-08 Erba Carlo Spa Use of the conjugate between a fibroblast growth factor and a saporin in treating ocular pathologies
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US6306421B1 (en) 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6395494B1 (en) * 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US5847007A (en) * 1993-05-13 1998-12-08 Neorx Corporation Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
US5770609A (en) * 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US5981568A (en) * 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5595722A (en) * 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
DE69435318D1 (de) * 1993-01-28 2010-12-09 Boston Scient Ltd Therapeutische inhibitoren der zellen der glatten gefässmuskulatur
US6663881B2 (en) * 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5599307A (en) * 1993-07-26 1997-02-04 Loyola University Of Chicago Catheter and method for the prevention and/or treatment of stenotic processes of vessels and cavities
US6551618B2 (en) 1994-03-15 2003-04-22 University Of Birmingham Compositions and methods for delivery of agents for neuronal regeneration and survival
US6037329A (en) * 1994-03-15 2000-03-14 Selective Genetics, Inc. Compositions containing nucleic acids and ligands for therapeutic treatment
US5824644A (en) * 1994-07-07 1998-10-20 G. D. Searle & Co. Method of attenuating arterial stenosis
WO1996006641A1 (fr) * 1994-08-29 1996-03-07 Prizm Pharmaceuticals, Inc. Conjugues du facteur de croissance endothelial vasculaire avec des agents cibles
US5665591A (en) * 1994-12-06 1997-09-09 Trustees Of Boston University Regulation of smooth muscle cell proliferation
CA2223595C (fr) * 1995-06-07 2008-08-05 Neorx Corporation Prevention et traitement de pathologies cardio-vasculaires au moyen d'analogues de tamoxifene
US7611533B2 (en) * 1995-06-07 2009-11-03 Cook Incorporated Coated implantable medical device
US5645839A (en) * 1995-06-07 1997-07-08 Trustees Of Boston University Combined use of angiotensin inhibitors and nitric oxide stimulators to treat fibrosis
AU3641297A (en) * 1996-06-24 1998-01-14 Prizm Pharmaceuticals, Inc. Heparinized medical devices containing heparin-binding growth factor conjugates
US20050043234A1 (en) 1996-10-16 2005-02-24 Deisher Theresa A. Novel FGF homologs
US6342051B1 (en) * 1997-06-12 2002-01-29 Gholam A. Peyman Treatment of anoxic tissue with angiogenesis-inducing implants
US6376471B1 (en) 1997-10-10 2002-04-23 Johns Hopkins University Gene delivery compositions and methods
DE19853067A1 (de) * 1998-11-17 2000-05-18 Jomed Implantate Gmbh Radioaktiver Stent
US6695830B2 (en) 1999-01-15 2004-02-24 Scimed Life Systems, Inc. Method for delivering medication into an arterial wall for prevention of restenosis
US7470665B2 (en) 1999-12-02 2008-12-30 Zymogenetics, Inc. Methods for targeting cells that express fibroblast growth receptor-3 or -2
US6827727B2 (en) * 2001-12-18 2004-12-07 Radi Medical Systems Ab Method and device for applying external pressure in combination with coagulant treatment of puncture wounds
DE10222776A1 (de) * 2002-05-15 2003-12-11 Neumann Till System zur wiederholten, aktiven Unterbrechung des Blutstroms
AU2003279835B2 (en) * 2002-10-07 2009-09-10 Zymogenetics, Inc. Methods of administering FGF18

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4956455A (en) * 1984-03-05 1990-09-11 The Salk Institute For Biological Studies Bovine fibroblast growth factor
ATE88900T1 (de) * 1987-09-02 1993-05-15 Ciba Geigy Ag Konjugate von interferon alpha mit immunglobulinen.
US5084556A (en) * 1987-10-23 1992-01-28 Genetics Institute, Inc. Composition of M-CSF conjugated to cytotoxic agents and a method for treating cancers characterized by over-expression of the c-fms proto-oncogene
US4950483A (en) * 1988-06-30 1990-08-21 Collagen Corporation Collagen wound healing matrices and process for their production
US5191067A (en) * 1989-04-27 1993-03-02 The Salk Institute For Biological Studies Fibroblast growth factor conjugates

Also Published As

Publication number Publication date
AU1193492A (en) 1992-08-17
WO1992011872A1 (fr) 1992-07-23
DE69204990T2 (de) 1996-05-15
US5308622A (en) 1994-05-03
ATE128034T1 (de) 1995-10-15
EP0565620B1 (fr) 1995-09-20
EP0565620A1 (fr) 1993-10-20
DE69204990D1 (de) 1995-10-26

Similar Documents

Publication Publication Date Title
DK0565620T3 (da) Mitotoxin til behandling af karbeskadigelse
Creech Jr et al. Experiences with isolation-perfusion technics in the treatment of cancer
Van Belle et al. Accelerated endothelialization by local delivery of recombinant human vascular endothelial growth factor reduces in-stent intimal formation
DE60132343D1 (de) Fgf-2 zur behandlung von erkrankungen der peripheralen arterien
JP2004523537A5 (fr)
ATE209908T1 (de) RADIKALFÄNGER (ßSPIN TRAPSß) ZUR BEHANDLUNG VON MIT OXIDATION VON LIPIDEN UND PROTEINEN VERBUNDENEN ERKRANKUNGEN
WO2001027079A3 (fr) Compositions et methodes d'utilisation de ligands liant des elements de la voie de coagulation sanguine pour le traitement du cancer et de maladies induites par le processus d'angiogenese
NO20015584L (no) Langtidsvarende insulintropiske peptider og konjugater samt anvendelse for fremstilling av medikamenter for behandling
IL91796A0 (en) Pharmaceutical preparations comprising gamma-interferon
WO2000021548A3 (fr) Dose unitaire de fgf efficace du point de vue angiogenique et methode d'administration
EP0681475A4 (fr) Inhibiteur therapeutique de cellules de muscles vasculaires lisses
JP2002527401A5 (fr)
HK1075409A1 (en) Angiogenically effective unit dose of fgf-2 and method of use fgf-2
JP2016516071A (ja) 瘢痕形成を軽減するためのｓｄｆ−１の使用
CA2089820C (fr) Traitement d'etats physio-pathologiques tumorigenes a l'aide de produits de conjugaison cytotoxiques du facteur de croissance de fibroblastes
CA2498062A1 (fr) Conjugues de proteine de liaison du facteur de croissance insulinomimetique 4 et de poly(ethylene glycol)
EP0426924A1 (fr) Production de compositions avec la propriété de transporter des métaux pour faciliter la greffe de moelle osseuse histo-incompatible et pour contrôler les réactions immunes dans l'hôte
Cappendijk et al. A true aneurysm of the tibioperoneal trunk. Case report and literature review
Pavithran Relapse of paucibacillary leprosy after short course multidrug therapy
Furrer et al. Lack of antitumour activity of human recombinant tumour necrosis factor-α, alone or in combination with melphalan in a nude mouse human melanoma xenograft system
Blakey et al. What's new: Immunotoxins
Weiß et al. The addition of human albumin to vinorelbine solution prevents venous irritation
Mesrobian The addition of three variants of subcutaneous flaps can improve the results of urethroplasty
PTGA et al. Synergistic effects of TNF-a and melphalan in an isolated limb perfusion model of rat sarcoma: a histopathological, immunohistochemical and electron microscopical study
Badgwell et al. Intra-arterial administration of TNF-α followed by arterial ablation is an effective therapy for a regionally confined TNF-resistant rat mammary adenocarcinoma